| Acute respiratory distress syndrome |
50 (35.0%) |
38 (35.5%) |
12 (33.3%) |
0.812 |
| Septic shock requiring vasopressors |
24 (16.8%) |
17 (15.9%) |
7 (19.4%) |
0.621 |
| Hemodialysis |
18 (12.6%) |
12 (11.2%) |
6 (16.7%) |
0.394 |
| Venous thromboembolism |
18 (12.6%) |
16 (15.0%) |
2 (5.6%) |
0.243 |
| Arterial thrombosis |
4 (2.8%) |
3 (2.8%) |
1 (2.8%) |
1.000 |
| Extracorporeal membrane oxygenation |
3 (2.1%) |
2 (1.9%) |
1 (2.8%) |
1.000 |
| Echocardiogram |
(n = 55) |
(n = 46) |
(n = 9) |
|
| Left ventricular ejection fraction (%) |
57.8 ± 11.3 |
58.2 ± 10.0 |
56.8 ± 14.9 |
0.696 |
| Right ventricular dysfunction |
18 (32.7%) |
12 (29.3%) |
6 (42.9%) |
0.349 |
| Labs |
|
|
|
|
| Peak Troponin (ng/ml), median (IQR) |
0.04 (0.18) |
0.03 (0.11) |
0.18 (0.97) |
0.004 |
| Peak BNP (pg/ml), median (IQR) |
117 (293) |
114 (249) |
150 (380) |
0.256 |
| Peak CRP (mg/dl), median (IQR) |
109 (154) |
97 (141) |
181 (154) |
0.029 |
| Peak Interleukin-6 (pg/ml), median (IQR) |
42 (199) |
30 (131) |
246 (664) |
0.003 |
| Treatment |
|
|
|
|
| Azithromycin |
85 (59.4%) |
64 (59.8%) |
21 (58.3%) |
0.876 |
| Hydroxychloroquine |
90 (62.9%) |
70 (65.4%) |
20 (55.6%) |
0.289 |
| Tocilizumab |
56 (39.2%) |
44 (41.1%) |
12 (33.3%) |
0.408 |
| Lopinavir/Ritonavir |
3 (2.1%) |
3 (2.8%) |
0 (0.0%) |
0.572 |
| Remdesivir |
13 (9.1%) |
12 (11.2%) |
1 (2.8%) |
0.185 |
